Genenta Scienceis A Clinical Stagebiotechnology Company Based In Milanitalyfocused On Developing Hematopoietic Stem Cell Based Genetherapies For Solid Tumor Cancersfounded In 2014Thecompany Utilizes A Proprietary Platform To Deliver Immunomodulatory Molecules Directly To Tumors Through Engineered Myeloid Cellsled By Ceo Pierluigi Paracchigenenta Went Public On Nasdaq In December 2021 Thecompany S Lead Candidatetemferona Caims To Enhancetheimmuneresponseagainst Tumors By Delivering Interferon Idirectly To Thetumor Microenvironmenttemferon Has Completed A Phase1 Trial In Newly Diagnosed Glioblastoma Multiformepatients And Is Set To Enter A Phase1 2A Trial For Metastatic Renal Cell Carcinomagenenta S Innovativeapproach Seeks To Reprogram Thetumor Microenvironmentmaking It Moreresponsiveto Treatmentand Has Potential Applications Across Various Solid Tumorsthecompany Is Committed To Advancing Its Clinical Pipelineto Meet Theneeds Of Patients With High Unmet Medical Needs
